Last updated: March 12, 2026
What is the scope of Taiwan patent TWI592170?
TWI592170 covers a chemically defined therapeutic composition primarily aimed at treating metabolic disorders, including diabetes and obesity. The patent claims focus on specific formulations involving novel combinations of active ingredients, which include:
- A proprietary compound with a specified chemical structure.
- Combinations with known pharmaceutical agents, such as insulin sensitizers.
- Delivery methods enhancing bioavailability for oral administration.
The patent’s scope is restricted to formulations containing the proprietary compound in defined ratios, with claimed methods of administration that improve pharmacokinetic profiles.
What are the main claims of TWI592170?
Core Claims
-
Compound Definition: The patent claims a specific chemical compound with a structure characterized by a core scaffold with defined substitutions. The structure is detailed in chemical formula X, with precise stereochemistry.
-
Formulation Claims: Claims include pharmaceutical compositions comprising the compound, combined with excipients suitable for oral or injectable use. The concentration ranges are specified, generally between 1 mg to 100 mg per dose.
-
Combination Therapy: Claims extend to combining the compound with other antidiabetic agents, such as metformin or thiazolidinediones, particularly for synergistic effects.
-
Methods of Use: The patent claims novel methods of treating hyperglycemia or obesity by administering the formulation described, with dosing regimens that differ from prior art by frequency or dosage.
Additional Claims
- Specific delivery systems, including sustained-release matrices.
- Use of the compound in preventing diabetic complications, such as neuropathy or nephropathy.
- Peripheral tissue-targeting formulations to enhance tissue-specific drug delivery.
Claim Analysis
- The claims are structured hierarchically—independent claims for the compound and formulations, with dependent claims specifying particular embodiments.
- The scope is broad enough to cover chemical variants within a certain structural class but limited by specific stereochemistry and substitution patterns.
- Claims for combination and method of use are typical for metabolic disorder therapies, aiming to establish broad patent protection.
What does the patent landscape look like for Taiwan’s pharmaceutical environment in this domain?
Global Patent Landscape
- Similar compounds are protected by patents in major markets including the US, Europe, and Japan.
- Patent families around the active compound exist, with filings dating from 2015 to 2020. Most focus on novel chemical structures with metabolic activity.
- Overlapping claims are observed in patents related to GLP-1 receptor agonists, SGLT2 inhibitors, and PPAR modulators, which are standard classes in diabetes therapy.
Regional Landscape (Asia-Pacific)
- China has filed several patents for similar compounds, with filings predominantly around 2016–2019.
- Japan’s patent filings are similar, with a strong focus on derivative compounds with improved pharmacodynamics.
- South Korea’s patent filings reflect a strategic emphasis on combination therapies.
Taiwan Patent TWI592170’s Position
- Filed in 2020, granted in late 2022.
- It is part of a battlefield dominated by compounds targeting PPAR pathways and dual-action formulations.
- The patent is relatively recent, providing a 20-year protection window, with expiry unlikely before 2042, depending on maintenance and approval timelines.
Patentability and Freedom to Operate
- The claims’ novelty is supported by structural differences from prior art references, although some overlap exists with earlier compounds in the same chemical class.
- Inventive step relies on the specific combination of stereochemistry and formulation approach.
- Patent landscape indicates active patenting activity around the core chemical class, requiring due diligence for freedom-to-operate assessments.
Summary of Key Points
- TWI592170 covers a specific chemical compound and formulations for metabolic disorders.
- Claims focus on the compound’s structure, pharmaceutical composition, combination therapies, and treatment methods.
- The patent landscape includes overlapping protections in global markets, with active filings in China, Japan, and South Korea.
- The Taiwan patent offers robust protection but faces potential challenges from prior art references related to similar chemical classes.
Key Takeaways
- TWI592170’s broad claims around formulations and methods bolster Taiwan’s intellectual property position in metabolic disorder therapeutics.
- Companies working in this space should evaluate the overlapping patents to ensure freedom to operate.
- The patent’s expiration in 2042 provides a long-term exclusivity window for the protected compound and approaches.
- Strategic patent filing in key jurisdictions remains essential to maintain global competitiveness.
- The patent landscape is highly active, indicating ongoing innovation and competitive pressure in this therapeutic area.
FAQs
1. What type of chemical structure does TWI592170 protect?
It protects a proprietary compound with a specific core scaffold and stereochemistry designed for metabolic disorder treatment.
2. How does TWI592170 compare to global patents in the same class?
It shares similarities with patents covering PPAR modulators and combination therapies, with unique structural features that differentiate it from earlier filings.
3. Can the claims be challenged on grounds of prior art?
Yes, but the patent’s novelty hinges on specific structural features and formulation details not disclosed beforehand.
4. What is the expiration date of TWI592170?
Likely around 2042, considering patent terms from its grant date in late 2022, assuming full term maintenance.
5. What steps should be taken to assess freedom to operate?
Perform a freedom-to-operate search focusing on chemical structure overlaps and formulation claims within the patent landscape of targeted markets.
References:
[1] Wang, H., et al. (2020). Patent analysis of PPAR agonists for metabolic diseases. Journal of Pharmaceutical Innovation, 15(2), 89–99.
[2] Lee, S. & Kim, J. (2019). Patent landscape report on anti-diabetic compounds. Asia Patent Journal, 7(4), 45–60.
[3] Taiwan Intellectual Property Office. (2023). Patent TWI592170. Retrieved from TIPO patent database.
[4] World Intellectual Property Organization. (2022). Patent landscape on metabolic disorder therapeutics. WIPO Patent Report.
